Mesa Laboratories (NASDAQ:MLAB) Releases Earnings Results, Beats Estimates By $0.66 EPS

Mesa Laboratories (NASDAQ:MLAB) released its earnings results on Tuesday. The medical instruments supplier reported $3.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.41 by $0.66, FiscalAI reports. The company had revenue of $65.13 million during the quarter, compared to analyst estimates of $63.23 million. Mesa Laboratories had a positive return on equity of 21.59% and a negative net margin of 0.64%.

Mesa Laboratories Stock Up 2.2%

Shares of MLAB opened at $80.50 on Tuesday. The company has a current ratio of 2.02, a quick ratio of 1.44 and a debt-to-equity ratio of 0.95. The business’s 50 day moving average is $81.28 and its 200 day moving average is $74.37. Mesa Laboratories has a 12-month low of $55.45 and a 12-month high of $155.12. The company has a market capitalization of $444.36 million, a PE ratio of -251.56 and a beta of 0.89.

Mesa Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Shareholders of record on Saturday, February 28th will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $0.64 dividend on an annualized basis and a yield of 0.8%. Mesa Laboratories’s dividend payout ratio (DPR) is currently -200.00%.

Institutional Investors Weigh In On Mesa Laboratories

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Boston Partners boosted its stake in shares of Mesa Laboratories by 2,009.5% in the third quarter. Boston Partners now owns 114,357 shares of the medical instruments supplier’s stock worth $7,664,000 after acquiring an additional 108,936 shares during the last quarter. Millennium Management LLC grew its stake in shares of Mesa Laboratories by 131.9% in the third quarter. Millennium Management LLC now owns 133,817 shares of the medical instruments supplier’s stock valued at $8,967,000 after buying an additional 76,107 shares in the last quarter. Kennedy Capital Management LLC grew its stake in shares of Mesa Laboratories by 34.3% in the third quarter. Kennedy Capital Management LLC now owns 121,546 shares of the medical instruments supplier’s stock worth $8,145,000 after acquiring an additional 31,067 shares in the last quarter. Select Equity Group L.P. grew its holdings in Mesa Laboratories by 38.3% during the 2nd quarter. Select Equity Group L.P. now owns 102,198 shares of the medical instruments supplier’s stock worth $9,629,000 after acquiring an additional 28,301 shares in the last quarter. Finally, Gabelli Funds LLC acquired a new position in shares of Mesa Laboratories during the 2nd quarter worth about $2,370,000. 90.60% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on MLAB shares. Zacks Research raised Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Mesa Laboratories in a report on Thursday, January 22nd. Wall Street Zen raised Mesa Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Wells Fargo & Company boosted their target price on Mesa Laboratories from $75.00 to $83.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $83.00.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.